Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A randomized study of oral vs intravenous iron supplementation in patientswith progressive renal insufficiency treated with erythropoietin
Autore:
Stoves, J; Inglis, H; Newstead, CG;
Indirizzi:
St James Univ Hosp, Dept Nephrol, Leeds LS9 7TF, W Yorkshire, England St James Univ Hosp Leeds W Yorkshire England LS9 7TF W Yorkshire, England
Titolo Testata:
NEPHROLOGY DIALYSIS TRANSPLANTATION
fascicolo: 5, volume: 16, anno: 2001,
pagine: 967 - 974
SICI:
0931-0509(200105)16:5<967:ARSOOV>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
LEFT-VENTRICULAR HYPERTROPHY; RECOMBINANT-HUMAN-ERYTHROPOIETIN; HEMODIALYSIS-PATIENTS; PREDIALYSIS PATIENTS; DIALYSIS PATIENTS; ANEMIA; FAILURE; CONSEQUENCES; DEFICIENCY; THERAPY;
Keywords:
anaemia; ferritin; haemoglobin; iron; iron sucrose; progressive renal insufficiency;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Stoves, J St James Univ Hosp, Dept Renal Med, Beckett St, Leeds LS9 7TF, WYorkshire, England St James Univ Hosp Beckett St Leeds W Yorkshire EnglandLS9 7TF
Citazione:
J. Stoves et al., "A randomized study of oral vs intravenous iron supplementation in patientswith progressive renal insufficiency treated with erythropoietin", NEPH DIAL T, 16(5), 2001, pp. 967-974

Abstract

Background. Correction of anaemia as a result of renal failure improves cardiovascular function and also provides significant cognitive and emotionalbenefits. The most appropriate route for iron supplementation has not beendetermined for patients with chronic renal failure who are not yet on dialysis. Methods. Forty-five anaemic patients with progressive renal insufficiency (PRI) were prospectively randomized to receive oral (ferrous sulphate 200 mg tds) or intravenous (300 mg iron sucrose monthly) iron treatment. Erythropoietin (rHuEpo) was simultaneously commenced and the dose adjusted according to a pre-established protocol. Results. There were no significant differences in baseline patient characteristics between the two groups. The average follow-up was 5.2 months. Three patients suffered possible allergic reactions to iron sucrose. Haemoglobin response and changes in red cell hypochromasia were similar in the two groups, but serum ferritin was significantly higher in the intravenous group. The starting dose of rHuEpo could be temporarily discontinued in 43% of patients on oral iron and 33% of patients receiving iron sucrose (NS). rHuEpowas increased after 3 months in 9% of patients on oral iron and 19% of patients receiving iron sucrose (NS). Final doses of rHuEpo were 33.5 (0-66) and 41.6 (0-124) U/kg/week respectively in the oral and intravenous groups (NS). Although gastro-intestinal symptoms were more commonly reported in patients caking oral iron, these were mild according to scores on visual analogue scales. Dietary protein and energy intake were not significantly different in the two groups at 0, 3 and 6 months. Conclusions, In pre-dialysis patients, the efficacy of monthly 300 mg ironsucrose given intravenously is not superior with regard to haemoglobin response and rHuEpo dose as compared with a daily oral dose of 600 mg of ferrous sulphate or equivalent. Where intravenous iron is prefer-red, lower doses may help to reduce the incidence of allergic or 'free iron' reactions. especially in patients with low body mass.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 00:10:33